DIAMINOHETEROCYCLIC CARBOXAMIDE COMPOUND Russian patent published in 2014 - IPC C07D239/48 C07D239/50 C07D241/26 C07D401/12 C07D401/14 C07D403/12 C07D405/12 C07D405/14 C07D409/12 C07D413/12 C07D417/12 C07D471/08 C07D491/113 A61K31/513 A61K31/506 A61K31/4965 A61K31/497 A61K31/538 A61P35/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: compounds can find application for preventing or treating cancer, lung cancer, non-small cells lung cancer, small-cell lung cancer, EML4-ALK hybrid polynucleotide-positive cancer, EML4-ALK hybrid polynucleotide-positive lung cancer or EML4-ALK hybrid polynucleotide-positive non-small cells lung cancer. In formula (I) -X-: group of formula , A represents chlorine, ethyl or isopropyl; R¹ represents phenyl wherein carbon in the 4^th position is substituted by the group -W-Y-Z, and carbon in the 3^rd position can be substituted by a group specified in a group consisting of halogen, R⁰⁰ and -O-R⁰⁰; R⁰⁰: lower alkyl which can be substituted by one or more halogen atoms; -W-: a bond, piperidine-1,4-diyl or piperazine-1,4-diyl; -Y- represents a bond; Z represents a monovalent 3-10-membered monocyclic non-aromatic heterocyclic ring which contains 1 to 4 heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, which can be substituted by one or more substitutes R⁰⁰; R² represents (i) an optionally bridged saturated C_3-10cycloalkyl which can be substituted by one or more groups specified in -N(lower alkyl)₂, lower alkyl, -COO-lower alkyl, -OH, -COOH, -CONH-R^ZB and morpholinyl, or (ii) a monovalent 3-10-membered monocyclic non-aromatic heterocyclic ring which contains 1 to 4 heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, which can be substituted by one or more groups specified in a group consisting of lower alkyl, -CO-lower alkyl, oxo, -CO-R^ZB and benzene; and R^ZB: phenyl which can be substituted by a group consisting of halogen and -O-lower alkyl; R³ represents -H.

EFFECT: invention refers to new compounds of formula or their pharmaceutically acceptable salts possessing the properties of a selective inhibitor of EML4-ALK hybrid protein kinase activity.

16 cl, 201 tbl, 582 ex